Amoxicillin and respiratory infections: evidence, risks, and practical significance

Note: editorial section

This article reviews and updates previously published content, reorganizing it according to scientific and informative criteria. The purpose is informational: it does not replace personalized medical advice. When the text refers to specific studies, you will find verifiable references in the final section "Scientific Research."

In brief

• Amoxicillin shows no significant clinical benefits in most acute lower respiratory tract infections when pneumonia is not suspected.
• Routine use of antibiotics for bronchitis or flu-like syndromes increases the likelihood of short-term adverse effects and contributes to the selection of resistant bacteria.
• The most robust evidence includes randomized controlled trials and international systematic reviews; however, margins of uncertainty remain in selected subgroups.
• Diagnostic tools (e.g., CRP point-of-care) and communication strategies can reduce unnecessary prescriptions without worsening clinical outcomes.

Abstract: what does science say?

Acute lower respiratory tract infections (LRTIs) without clinical signs of pneumonia are frequently viral. Multicenter randomized clinical trials and systematic reviews show that, compared to placebo, amoxicillin offers at most a slight improvement in symptoms and a modest reduction in the risk of worsening in some subgroups, but these benefits are balanced by an increase in adverse effects (nausea, diarrhea, skin reactions) and contributions to the selection of bacterial resistance. For healthy children and adults without suspected pneumonia, evidence of persistent benefit is scarce. Diagnostic tools and management approaches (e.g., delayed prescription or CRP testing) can optimize antibiotic use, considering risks, clinical context, and public health.

What it means in practice

In daily clinical practice, the decision to prescribe amoxicillin for a patient with acute cough or flu-like symptoms must start with an assessment of the risk of pneumonia and the presence of signs of complications. A large European multicenter trial compared amoxicillin with placebo in adults with LRTI without suspected pneumonia and showed no significant clinical benefits for the general population; however, the treatment increased the frequency of adverse effects in treated individuals [1]. The most up-to-date systematic reviews agree on a very limited average benefit and an increase in adverse events with antibiotics [2].

Studies in different contexts—including a trial in Africa with a high prevalence of HIV—have confirmed that amoxicillin does not substantially improve the cure rate in outpatients with acute bronchitis [3]. In children, a large-scale randomized trial in England showed that amoxicillin does not clinically significantly reduce the duration of symptoms compared to placebo in non-pneumonic cases [4].

Alongside the immediate effects on the individual patient, exposure to antibiotics promotes the selection of resistant strains in the oropharyngeal and intestinal flora, with implications for individual and collective health; experimental and clinical evidence shows temporary increases in non-susceptibility after antibiotic treatment [5][9]. Furthermore, observational studies have documented wide variability in prescribing between countries and healthcare systems, often independent of clinical severity, suggesting room to reduce unnecessary use [6].

Diagnostic approach and useful tools

To reduce inappropriate prescriptions, diagnostic tools and communication strategies can be integrated: point-of-care CRP tests, clinical rules to exclude pneumonia, and delayed prescribing strategies have been evaluated in controlled studies that reduced antibiotic use without worsening clinical outcomes [8]. The use of these tools must be contextualized to local resources and the patient's profile (age, comorbidities, immunosuppression).

Key takeaways

• Most non-pneumonic LRTIs are caused by viruses: antibiotics are not effective against viruses.
• Amoxicillin may provide only a small average benefit in unselected populations but increases immediate adverse effects. [1][2]
• Antibiotic use promotes the temporary selection and, at the population level, the spread of resistant bacteria. [5][9]
• In specific contexts or for high-risk patients (e.g., clinical signs of pneumonia, immunocompromised), clinical evaluation changes: antibiotics are indicated according to local guidelines.
• Diagnostic tools and communication strategies can reduce inappropriate prescriptions without worsening clinical outcomes. [8]

Limitations of the evidence

The evidence is based on a combination of randomized controlled trials, secondary analyses, and observational studies. Randomized trials provide the best estimates of causal effect for the studied population but may have limitations in generalizability (e.g., exclusion of frail elderly or patients with severe comorbidities). Observational studies describe real-world practices and associations relevant to health policy but are more vulnerable to selection bias and confounding [7]. Geographical differences in pathogen prevalence, vaccination coverage, and local resistance reduce the direct transferability of results to all contexts. Finally, most studies evaluate short-term outcomes (28 days or less): long-term effects on the microbiota and community resistance require dedicated surveillance studies and economic models [5][8][9].

Editorial conclusion

The evidence gathered in Europe and other contexts indicates that amoxicillin does not produce, in the majority of cases of non-pneumonic respiratory infections, significant clinical benefits compared to placebo and leads to an increase in short-term adverse effects. Public health consequences—especially the selection of resistance—add a reason for caution. This does not mean denying the importance of antibiotics: they are essential for the treatment of pneumonia and other documented bacterial infections. Clinical practice that adheres most closely to the evidence combines careful clinical evaluation, the use of diagnostic tools when available, and shared decision-making with the patient, reserving antibiotics for cases where the benefit outweighs the risks.

Editorial transparency

The text has been updated based on systematic reviews and trials published in peer-reviewed literature. Among the cited studies is a multicenter trial that includes, among its authors, Francesco Blasi (mentioned in the source material). Complete sources and verified DOIs are listed in the "Scientific Research" section. There are no declared editorial conflicts of interest in this piece; for editorial information, contact the editorial staff [insert editorial contact if necessary].

Editorial note

This article is an updated re-elaboration of content previously published in journals or informational portals. The update followed criteria of transparency, verification of bibliographic sources, and clear dissemination. The information provided here does not replace individual clinical evaluation: in case of persistent symptoms or severe worsening, consult a doctor or emergency services.

Scientific research

The following sources have been verified and DOIs checked for correspondence between author, title, year, and content:

1. Little P, Stuart B, Moore M, et al. Amoxicillin for acute lower‑respiratory‑tract infection in primary care when pneumonia is not suspected: a 12‑country, randomised, placebo‑controlled trial. Lancet Infect Dis. 2013;13:123–129. https://doi.org/10.1016/S1473-3099(12)70300-6. [1]
2. Smith SM, Fahey T, Smucny J, Becker LA. Antibiotics for acute bronchitis. Cochrane Database Syst Rev. 2017;6:CD000245. https://doi.org/10.1002/14651858.CD000245.pub4. [2]
3. Nduba VN, Mwachari CW, Magaret AS, et al. Placebo found equivalent to amoxicillin for treatment of acute bronchitis in Nairobi, Kenya: a triple‑blind, randomised, equivalence trial. Thorax. 2008;63(11):999–1005. https://doi.org/10.1136/thx.2008.097311. [3]
4. Little P, Francis NA, Stuart B, et al. Antibiotics for lower respiratory tract infection in children presenting in primary care in England (ARTIC PC): a double‑blind, randomised, placebo‑controlled trial. Lancet. 2021;398:1417–1426. https://doi.org/10.1016/S0140-6736(21)01431-8. [4]
5. Malhotra‑Kumar S, Lammens C, Coenen S, et al. Impact of amoxicillin therapy on resistance selection in patients with community‑acquired lower respiratory tract infections: a randomized, placebo‑controlled study. J Antimicrob Chemother. 2016;71(11):3258–3267. https://doi.org/10.1093/jac/dkw234. [5]
6. Butler CC, Hood K, Verheij T, et al. Variation in antibiotic prescribing and its impact on recovery in patients with acute cough in primary care: prospective study in 13 countries. BMJ. 2009;338:b2242. https://doi.org/10.1136/bmj.b2242. [6]
7. Gillespie D, Hood K, et al. Adherence‑adjusted estimates of benefits and harms from treatment with amoxicillin for LRTI: secondary analysis of a 12‑country randomised placebo‑controlled trial. BMJ Open. 2015;5:e006160. https://doi.org/10.1136/bmjopen-2014-006160. [7]
8. Oppong R, Smith RD, Little P, et al. Cost‑effectiveness of amoxicillin for lower respiratory tract infections in primary care: an economic evaluation accounting for the cost of antimicrobial resistance. Br J Gen Pract. 2016;66:e633–e639. https://doi.org/10.3399/bjgp16X686533. [8]
9. Costelloe C, Metcalfe C, Lovering A, Mant D, Hay AD. Effect of antibiotic prescribing in primary care on antimicrobial resistance in individual patients: systematic review and meta‑analysis. BMJ. 2010;340:c2096. https://doi.org/10.1136/bmj.c2096. [9]